AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3

AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3
A Phase 2 trial (NCT02365649) of AbbVie’s investigational compound upadacitinib (ABT-494) showed the treatment had a positive effect in patients with Crohn’s disease, supporting the drug's advance to Phase 3 trials. Data from the trial, called CELEST, was presented at the Digestive Disease Week 2017 conference May 6-9 in Chicago. The study had particularly focused on patients who had failed previous treatments with immunomodulating drugs or TNF inhibitors, and all patients had moderately to severely active disease. Researchers recruited 220 patients, who were randomized to receive placebo or one of five upadacitinib dose regimens for 16 weeks.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *